Udvalget for Humanmedicinske Lægemidler (CHMP) besluttede, at fordelene ved Avandia A er større end risiciene ved behandling af type 2- diabetes.
The Committee for Medicinal Products for Human Use (CHMP) decided that Avandia’ s benefits are greater than its risks for the treatment of type 2 diabetes mellitus.